Serina Therapeutics Inc

Serina Therapeutics, Inc. is a biotechnology company that develops drugs for neurological diseases and pain. Its lead candidate, SER 252 (POZ-apomorphine), is a POZ conjugate in phase 1 clinical trials for advanced Parkinson's disease, alongside POZ-lipids, a non-immunogenic alternative to PEG-lipids used in lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for early Parkinson's disease and Restless Leg Syndrome, which has completed a phase 1a clinical trial, and applies its POZ technology to lipid nanoparticle-delivered RNA vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Founded in 2006, Serina Therapeutics is headquartered in Huntsville, Alabama.

Biotech & Genomic Medicine▲2

Gannet BioChem and Serina Therapeutics Enter Development Partnership for SER-252

Gannet BioChem and Serina Therapeutics have entered a development partnership to support SER-252, Serina's investigational therapy for advanced Parkinson's disease. Under the agreement, Gannet BioChem will provide process development, scale-up, and manufacturing support for the program, which recently received FDA clearance of its Investigational New Drug application. The collaboration combines Serina's proprietary POZ Platform technology with Gannet BioChem's expertise in complex therapeutic manufacturing. Serina's CEO Steve Ledger stated the partnership will help unlock the full potential of the POZ Platform in neurology and beyond, while Gannet BioChem's CEO Nicholas Shackley highlighted the company's technical expertise in supporting innovative therapies through critical development stages.

SER ▲

Biotech & Genomic Medicine

GlobeNewswire·80dRead more →